Previous 10 | Next 10 |
home / stock / vphif / vphif news
VALEO PHARMA ENTERS INTO CANADIAN COMMERCIAL SERVICES AGREEMENT WITH VERU FOR SABIZABULIN IN HOSPITALIZED ADULT PATIENTS WITH COVID-19 AT HIGH RISK FOR ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Canada NewsWire In a Phase 3 cinical study interim analysis, sabizabulin...
Valeo Pharma press release ( OTCQB:VPHIF ): Q3 Revenue of $6.1M beats by $1.41M . Cash and liquidities of $27.7 million as at July 31, 2022 For further details see: Valeo Pharma reports Q3 results
VALEO PHARMA REPORTS RECORD THIRD QUARTER 2022 RESULTS AND HIGHLIGHTS Canada NewsWire Record revenues of $6.1 million in Q3-22, a 27% increase over Q2-22 Record Gross Margins of $2.2 million in Q3-22, up 34% over Q2-22 Record YTD-22 re...
VALEO PHARMA TO HOST THIRD QUARTER 2022 RESULTS CONFERENCE CALL / WEBCAST Canada NewsWire MONTREAL , Sept. 9, 2022 /CNW Telbec/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical...
VALEO PHARMA ADDS PHARMACEUTICAL INDUSTRY VETERAN KYLE STEIGER TO LEADERSHIP TEAM Canada NewsWire Kyle Steiger appointed Senior Vice-President and Chief Commercial Officer Jean-François Fournier appointed new Business Unit Head - Ophthalm...
VALEO PHARMA CLOSES US$40 MILLION NON-DILUTIVE FINANCING FROM SAGARD HEALTHCARE PARTNERS Canada NewsWire Proceeds to fund acquisition of Canadian rights to 3 growing commercial stage drugs Acquisition allows Valeo to expand into Ophthalmology and Allergy ...
VALEO PHARMA ENTERS INTO LICENSE AGREEMENT WITH KALÉO FOR THE CANADIAN RIGHTS TO ALLERJECT® Canada NewsWire 700,000 Canadians suffering from severe allergies Canadian epinephrine auto-injector market exceeds $80M annually ALLERJE...
VALEO PHARMA ENTERS INTO AN AGREEMENT FOR OPHTHALMIC PRODUCTS, PrXIIDRA® AND PrSIMBRINZA®, IN CANADA Canada NewsWire Ophthalmology becomes additional strategic therapeutic area Significant market opportunities with more than 6 million 1 Canadian...
Valeo Pharma press release (OTCQB:VPHIF): Q2 Net loss was C$5.1M Revenue of C$4.8M (+81.1% Y/Y). For further details see: Valeo Pharma reports Q2 results
VALEO PHARMA REPORTS ITS SECOND QUARTER 2022 RESULTS AND HIGHLIGHTS Canada NewsWire Q2-22 revenues of $4.8 million , up 80% over Q2-21 Q2-22 gross margins of $1.7 million , up 134% over Q2-21 Canadian provincial public reimbursement now co...
News, Short Squeeze, Breakout and More Instantly...
VALEO PHARMA ANNOUNCES SENIOR EXECUTIVE APPOINTMENT AND BOARD OF DIRECTORS CHANGE Canada NewsWire MONTREAL , June 18, 2024 /CNW/ - Valeo Pharma Inc . (TSX: VPH) (OTCQB: VPHIF) (FSE: VP2) (" Valeo " or the " Company "), a Canadian pharmaceutical compan...
(NewsDirect) Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to discuss the company's financial results for the second quarter, which saw record-breaking revenue for the period. The company reported revenues of $14.1 million for Q2, an increase from the $13.6 million rec...
VALEO PHARMA ANNOUNCES RESTRUCTURING OF COMMERCIAL FIELD OPERATIONS TO SUPPORT PATH TO PROFITABILITY Canada NewsWire Changes to respiratory business unit to generate more than $5 million in annual savings Follows previously announced cost saving measures exce...